WSO - July 2023 - 690

690
International Journal of Stroke 18(6)
Introduction
Large vessel occlusion (LVO) strokes are most commonly
caused by either cardioembolism (CE), of which atrial
fibrillation (AF) is the most common risk factor, or large
artery atherosclerosis (LAA). AF and cardioembolic etiology
have been reported to be associated with larger infarcts
and poorer clinical outcomes,1-3 particularly prior to the
advent of endovascular thrombectomy (EVT).
The poorer outcome of AF may be related to collaterals.
Collateral flow plays an important role in acute ischemic
stroke. Two studies reported that stroke due to CE or AF
was associated with lower collateral score graded on computed
tomography angiography (CTA) and worse clinical
outcome at 3 months compared with stroke due to cervical
carotid atherosclerosis.4,5 Conversely, other studies failed
to show an association between AF and CTA collateral
score.6 The conflict findings indicate a more complex relationship
may exist between AF and collaterals.
Moreover, a recent study indicates that the worse stroke
outcome in AF may be explained by more severe hypoperfusion.2
The severe hypoperfusion on perfusion imaging
can reflect collateral function,7,8 whereas the CTA collateral
score is based on visualization of collateral vessel structure
of the occluded vascular territory. Indeed, the central function
of collateral flow is to maintain cerebral blood flow in
regions that are hypoperfused.8
Aim
In this study, we aimed to explore the complex relationship
between AF, collateral flow, and severe hypoperfusion in
patients treated with EVT.
Methods
Study design
This was a retrospective cohort study, selecting LVO
patients who received EVT. Patients were classified into
two groups: (1) AF group and (2) No AF group. The diagnosis
of AF was made when patient history was positive for
AF or when AF was diagnosed during hospital stay.
Patients
This study included patients who were enrolled in
INternational Stroke Perfusion REgistry (INSPIRE). Data
in this study were collected between 2011 and 2020 and
from 22 sites (9 Australian, 12 Chinese, and 1 Canadian).
This study obtained ethical approval from Hunter New
England Human Research Ethics Committee (11/08/17/4.01),
and informed consent was obtained for each patient for their
data to be used as part of the INSPIRE registry.
The key inclusion criterion was LVO patients who were
treated with EVT (with or without bridging thrombolysis).
International Journal of Stroke, 18(6)
Severe hypoperfusion volume
Severe hypoperfusion volume was defined as the region
with delay time > 6s on acute CTP.7 Hypoperfusion intensity
ratio was defined as the ratio of the severe hypoperfusion
volume of delay time >6 s divided by the volume of
tissue with delay time >2 s on acute CTP.7
Patient outcomes
The primary outcome was good functional outcome (defined
as mRS of 0-2 at 3 months post-stroke). Secondary outcomes
included: (1) 3-month mortality, (2) parenchymal hematoma
(PH), (3) parenchymal hematoma type 2 (PH2), (4) symptomatic
hemorrhagic transformation (sICH) according to the
safe implementation of thrombolysis in stroke-monitoring
study (SITS-MOST) criteria, and (5) recanalization assessed
on post-EVT angiography with a Modified Thrombolysis in
Cerebral Infarction score of 2b or 3.
Statistical analysis
All statistical analyses were done using STATA 13.0 (Stata
Corp, College Station, TX, USA), with confidence interval
(CI) set at 95% and alpha level set at 0.05. Continuous data
were summarized as median and inter-quartile range (IQR);
Exclusion criteria were incomplete data in INSPIRE
regarding the history (current or past) of AF, age, or
3-month modified Rankin Scale (mRS).
Imaging parameters
Baseline CT imaging included brain non-contrast CT, CT
perfusion (CTP), and CTA. The baseline CTP raw data
were centrally processed by commercial software MIStar
(Apollo Medical Imaging Technology, Melbourne, VIC,
Australia). A threshold of >3 s in delay time was used to
delineate the perfusion lesion, within which tissue with cerebral
blood flow ⩽30% was identified as an infarct core.9
Collateral
Collateral flow was assessed on baseline CTA using the
Miteff scale.10 Collateral status was graded as good, moderate,
or poor (Y.W. and C.C.) depending on the extent of contrast
visualized distal to the occlusion. The definition to
grade collateral status is as follows: poor collateral flow in
superficial vessels only, moderate collateral flow into the
Sylvian fissure, and good collateral flow up to the occlusion.
The Miteff scale was developed on grading middle cerebral
artery. In this study, we expanded the definition to grade
posterior circulation as follows: poor collateral flow in
superficial vessels only, good collateral flow up to the occlusion,
and moderate collateral flow in between.

WSO - July 2023

Table of Contents for the Digital Edition of WSO - July 2023

Contents
WSO - July 2023 - Cover1
WSO - July 2023 - Cover2
WSO - July 2023 - 627
WSO - July 2023 - Contents
WSO - July 2023 - 629
WSO - July 2023 - 630
WSO - July 2023 - 631
WSO - July 2023 - 632
WSO - July 2023 - 633
WSO - July 2023 - 634
WSO - July 2023 - 635
WSO - July 2023 - 636
WSO - July 2023 - 637
WSO - July 2023 - 638
WSO - July 2023 - 639
WSO - July 2023 - 640
WSO - July 2023 - 641
WSO - July 2023 - 642
WSO - July 2023 - 643
WSO - July 2023 - 644
WSO - July 2023 - 645
WSO - July 2023 - 646
WSO - July 2023 - 647
WSO - July 2023 - 648
WSO - July 2023 - 649
WSO - July 2023 - 650
WSO - July 2023 - 651
WSO - July 2023 - 652
WSO - July 2023 - 653
WSO - July 2023 - 654
WSO - July 2023 - 655
WSO - July 2023 - 656
WSO - July 2023 - 657
WSO - July 2023 - 658
WSO - July 2023 - 659
WSO - July 2023 - 660
WSO - July 2023 - 661
WSO - July 2023 - 662
WSO - July 2023 - 663
WSO - July 2023 - 664
WSO - July 2023 - 665
WSO - July 2023 - 666
WSO - July 2023 - 667
WSO - July 2023 - 668
WSO - July 2023 - 669
WSO - July 2023 - 670
WSO - July 2023 - 671
WSO - July 2023 - 672
WSO - July 2023 - 673
WSO - July 2023 - 674
WSO - July 2023 - 675
WSO - July 2023 - 676
WSO - July 2023 - 677
WSO - July 2023 - 678
WSO - July 2023 - 679
WSO - July 2023 - 680
WSO - July 2023 - 681
WSO - July 2023 - 682
WSO - July 2023 - 683
WSO - July 2023 - 684
WSO - July 2023 - 685
WSO - July 2023 - 686
WSO - July 2023 - 687
WSO - July 2023 - 688
WSO - July 2023 - 689
WSO - July 2023 - 690
WSO - July 2023 - 691
WSO - July 2023 - 692
WSO - July 2023 - 693
WSO - July 2023 - 694
WSO - July 2023 - 695
WSO - July 2023 - 696
WSO - July 2023 - 697
WSO - July 2023 - 698
WSO - July 2023 - 699
WSO - July 2023 - 700
WSO - July 2023 - 701
WSO - July 2023 - 702
WSO - July 2023 - 703
WSO - July 2023 - 704
WSO - July 2023 - 705
WSO - July 2023 - 706
WSO - July 2023 - 707
WSO - July 2023 - 708
WSO - July 2023 - 709
WSO - July 2023 - 710
WSO - July 2023 - 711
WSO - July 2023 - 712
WSO - July 2023 - 713
WSO - July 2023 - 714
WSO - July 2023 - 715
WSO - July 2023 - 716
WSO - July 2023 - 717
WSO - July 2023 - 718
WSO - July 2023 - 719
WSO - July 2023 - 720
WSO - July 2023 - 721
WSO - July 2023 - 722
WSO - July 2023 - 723
WSO - July 2023 - 724
WSO - July 2023 - 725
WSO - July 2023 - 726
WSO - July 2023 - 727
WSO - July 2023 - 728
WSO - July 2023 - 729
WSO - July 2023 - 730
WSO - July 2023 - 731
WSO - July 2023 - 732
WSO - July 2023 - 733
WSO - July 2023 - 734
WSO - July 2023 - 735
WSO - July 2023 - 736
WSO - July 2023 - 737
WSO - July 2023 - 738
WSO - July 2023 - 739
WSO - July 2023 - 740
WSO - July 2023 - 741
WSO - July 2023 - 742
WSO - July 2023 - 743
WSO - July 2023 - 744
WSO - July 2023 - 745
WSO - July 2023 - 746
WSO - July 2023 - 747
WSO - July 2023 - 748
WSO - July 2023 - 749
WSO - July 2023 - 750
WSO - July 2023 - 751
WSO - July 2023 - 752
WSO - July 2023 - 753
WSO - July 2023 - 754
WSO - July 2023 - 755
WSO - July 2023 - 756
WSO - July 2023 - Cover3
WSO - July 2023 - Cover4
https://europe.nxtbook.com/nxteu/sageuk/wso_202404
https://europe.nxtbook.com/nxteu/sageuk/ukstrokeforum_202402_supp
https://europe.nxtbook.com/nxteu/sageuk/wso_202403
https://europe.nxtbook.com/nxteu/sageuk/wso_202402
https://europe.nxtbook.com/nxteu/sageuk/wso_202401
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_US_UKOnly
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_ROW
https://europe.nxtbook.com/nxteu/sageuk/wso_2023101
https://europe.nxtbook.com/nxteu/sageuk/wso_202308
https://europe.nxtbook.com/nxteu/sageuk/wso_202307
https://europe.nxtbook.com/nxteu/sageuk/wso_202306
https://europe.nxtbook.com/nxteu/sageuk/wso_202304
https://europe.nxtbook.com/nxteu/sageuk/wso_202303
https://europe.nxtbook.com/nxteu/sageuk/wso_202302
https://europe.nxtbook.com/nxteu/sageuk/wso_202301
https://www.nxtbookmedia.com